Your browser doesn't support javascript.
Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study.
Maronese, Carlo Alberto; Caproni, Marzia; Moltrasio, Chiara; Genovese, Giovanni; Vezzoli, Pamela; Sena, Paolo; Previtali, Giulia; Cozzani, Emanuele; Gasparini, Giulia; Parodi, Aurora; Atzori, Laura; Antiga, Emiliano; Maglie, Roberto; Moro, Francesco; Mariotti, Elena Biancamaria; Corrà, Alberto; Pallotta, Sabatino; Didona, Biagio; Marzano, Angelo Valerio; Di Zenzo, Giovanni.
  • Maronese CA; Dermatology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Caproni M; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Moltrasio C; Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, Unità Sanitaria Locale Toscana Centro, European Reference Network-Skin Member, University of Florence, Florence, Italy.
  • Genovese G; Dermatology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Vezzoli P; Department of Medical Surgical and Health Sciences, University of Trieste, Trieste, Italy.
  • Sena P; Dermatology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Previtali G; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Cozzani E; Dermatology Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Gasparini G; Dermatology Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Parodi A; Clinical Chemistry Laboratory, Department of Clinical Pathology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Atzori L; DiSSal, Dermatology Clinic, University of Genoa, San Martino Policlinic Hospital- Istituto di Ricovero e Cura a Carattere Scientifico, Genoa, Italy.
  • Antiga E; DiSSal, Dermatology Clinic, University of Genoa, San Martino Policlinic Hospital- Istituto di Ricovero e Cura a Carattere Scientifico, Genoa, Italy.
  • Maglie R; DiSSal, Dermatology Clinic, University of Genoa, San Martino Policlinic Hospital- Istituto di Ricovero e Cura a Carattere Scientifico, Genoa, Italy.
  • Moro F; Dermatology Clinic, Department Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Mariotti EB; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
  • Corrà A; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
  • Pallotta S; Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
  • Didona B; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
  • Marzano AV; Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.
  • Di Zenzo G; Dermatology Clinic, Istituto Dermopatico dell'Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
Front Med (Lausanne) ; 9: 841506, 2022.
Article in English | MEDLINE | ID: covidwho-2198968
ABSTRACT
Bullous pemphigoid (BP) is an autoimmune bullous disease caused by circulating autoantibodies toward the hemidesmosomal antigens BP180 and BP230. Cases of BP have been described following vaccinations against tetanus, poliomyelitis, diphtheria, influenza, pneumococcus, meningococcus, hepatitis B and rabies. The putative mechanism by which COVID-19-vaccines may induce BP has not been clarified. An Italian multicentre study was conducted to collect clinical, histopathological and immunopathological data of patients with BP associated with COVID-19-vaccines. Twenty-one cases were collected, including 9 females and 12 males (M/F = 1.3) with a median age at diagnosis of 82 years. Seventeen patients received the COMIRNATY Pfizer-BioNTech vaccine, two the Moderna mRNA-1273 vaccine, one the ChAdOx1/nCoV-19-AstraZeneca/ Vaxzevria vaccine and one received the first dose with the ChAdOx1/nCoV-19-AstraZeneca/Vaxzevria vaccine and the second dose with the COMIRNATY Pfizer-BioNTech vaccine. Median latency time between the first dose of anti-SARS-CoV-2 vaccine and the onset of cutaneous manifestations was 27 days. Median BPDAI at onset was 42. Eleven out of seventeen patients (65%) had positive titres for anti-BP180 antibodies with a median value of 106.3 U/mL on ELISA; in contrast, only five out of seventeen (29%) were positive for anti-BP230 antibodies, with a median of 35.3 U/mL. In conclusion, in terms of mean age, disease severity at diagnosis and clinical phenotype vaccine-associated BP patients seem to be similar to idiopathic BP with an overall benign course with appropriate treatment. On the other hand, the slight male predominance and the reduced humoral response to BP230 represent peculiar features of this subset of patients.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Journal: Front Med (Lausanne) Year: 2022 Document Type: Article Affiliation country: Fmed.2022.841506

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Journal: Front Med (Lausanne) Year: 2022 Document Type: Article Affiliation country: Fmed.2022.841506